Dr Komrokji on Ongoing Investigations With Luspatercept in M

Rami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.

Related Keywords

, University Of South Florida , Moffitt Cancer Center , Medicine Oncologic Sciences , Malignant Hematology Department , Experimental Therapeutics Program , College Of Medicine , Rami Komrokji , Malignant Hematology , Oncologic Sciences , South Florida , Onclive Tv ,